New Research from One Biosciences Shows Single-Cell Profiling Can Identify Which Ovarian Cancer Tumors are Predisposed to Chemotherapy Resistance

Contributed by: Business Wire

Logo

Tags

Oncology

Health

Consumer

Women

Clinical Trials

Pharmaceutical

Biotechnology

One Biosciences

More Like This

One Biosciences Announces Data Validating New Method for Single-Cell Transcriptomic Tumor Profiling from Clinical Pathology Samples

Gustave Roussy and One Biosciences Partner to Bring Single Cell to Clinical Practice for Precision Oncology

One Biosciences Receives BOOST Funding From Paris-Saclay Cancer Cluster to Advance the First Single-Cell Assay Approach for ADC Therapies

One Biosciences Receives €3,3 Million Funding Under i-Démo 5 From France 2030 to Accelerate Development of First Single-Cell Diagnostic for Triple-Negative Breast Cancer, in Collaboration With Institut Curie

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

Pioneering Cancer Plasticity Atlas will Help Predict Response to Cancer Therapies

PR Newswire associated0

Sengenics Corporation Unveils i-Ome® Cancer: A Breakthrough in Cancer Precision Medicine

PR Newswire associated0

J INTS BIO Presents Interim Results from the Preclinical Study of 'JIN-001' in Refractory Ovarian Cancer: A Promising Solution for Overcoming Drug Resistance